Menu Search
Equities

Chemometec A/S

CHEMM:CPH

Chemometec A/S

Actions
Health CareMedical Equipment and Services
  • Price (DKK)427.60
  • Today's Change-1.60 / -0.37%
  • Shares traded27.66k
  • 1 Year change+17.28%
  • Beta1.4822
Data delayed at least 15 minutes, as of Sep 19 2024 16:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 13-Sep-24
Select bar for recommendation details.
Recommendations13-Sep-24
Buy2
Outperform0
Hold0
Sell1
Strong Sell0

Share price forecast in DKK

The 3 analysts offering 12 month price targets for ChemoMetec A/S have a median target of 470.00, with a high estimate of 505.00 and a low estimate of 335.00. The median estimate represents a 9.92% increase from the last price of 427.60.
High18.1%505.00
Med9.9%470.00
Low-21.7%335.00

Dividends

Historical dividend information is not available for Chemometec A/S.
Div growth (TTM)--
More ▼

Earnings history & estimates in DKK

ChemoMetec A/S reported annual 2024 earnings of 7.83 per share on Sep 11, 2024.
Average growth rate-5.82%
More ▼

Revenue history & estimates in DKK

ChemoMetec A/S had 4th quarter 2024 revenues of 109.30m. This bettered the 104.00m estimate of the one analyst covering the company. This was 3.95% below the prior year's 4th quarter results.
Average growth rate+0.92%
ChemoMetec A/S had revenues for the full year 2024 of 407.35m. This was 7.90% below the prior year's results.
Average growth rate-2.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.